
	Chemical structure search How to Search	Import MOLfile format is only available (V3000 format is not available) Exact match Substructure search Superstructure search Substructure or superstructure search Similarity search

Rchr

J-GLOBAL ID：200901066570999426 Update date: Mar. 05, 2025

Matsumoto Masanori

マツモトマサノリ | Matsumoto Masanori

Affiliation and department：
Job title： Associate Professor

Research field (1)： Hematology and oncology

Research keywords (2)：血液内科学 , Hematology

Research theme for competitive and other funds (41)：

2024 - 2027 Development of a platform for evaluating the environmental response to von Willebrand factor during circulatory assist
2022 - 2027 Platform design for von Willebrand factor response evaluation in circulatory support
2024 - 2026 Pathophysiological analysis and therapeutic development based on vWF-ADAMTS13 regulation for poor prognostic factors in liver cirrhosis
2022 - 2025 後天性・血栓性血小板減少性紫斑病の動物モデルの作成
2020 - 2023 A novel strategy in diagnosis and therapy for acquired vonwillebrand syndrome associated with cardiovascular disease

2021 - 2023 Development research of novel pathophysiology and therapy for hepatorenal syndrome in cirrhosis-Thrombotic microangiopathy and recombinant ADAMTS13 therapy-

2020 - 2021 消化器癌における静脈血栓塞栓症機序の新概念と次世代型抗血栓療法の開発

2018 - 2021 難治性疾患実用化研究事業高ずり応力を伴う循環器難病に随伴する出血性合併症予知法の開発

2017 - 2020 重症大動脈弁狭窄症に合併する消化管出血のフォンビレブランド因子による病態解析

2017 - 2020 難治性疾患実用化研究事業植込型補助人工心臓装着後の出血性合併症予知法および予防法の確立に関する研究

2017 - 2020 難治性疾患実用化研究事業機械的補助循環に合併する後天性von Willebrand症候群の治療法の開発

2017 - 2020 難治性疾患実用化研究事業非典型溶血性尿毒症症候群(aHUS)の複合的アプローチによる診断と治療向上に関する研究

2016 - 2019 Involvement of ADAMTS 13 in liver failure after hepatectomy and establishment of novel liver failure treatment strategy

2017 - 2019 難治性疾患等政策研究事業血液凝固異常症等に関する研究

2016 - 2019 医薬品等規制調和・評価研究事業さらなる適正使用に向けた、血液製剤の使用と輸血療法の実施に関する研究

2015 - 2018 Study on the effects of thrombomodulin on the vascular endothelial damages in GVHD model

2014 - 2017 Establishment of new treatment targeting lifestyle diseases and coagulation fibrinolytic system related to the development of NASH

2013 - 2016 Development of novel methods for diagnosis and management of thrombotic microangiopathy following stem cell transplantation

2014 - 2015 Extracellular histones stimulate endothelial cells to release unusually-large von Willebrand factor multimer: mechanistic insight into the pathogenesis of lethal coagulopathy

2013 - 2015 Establishment of the diagnostic system of patients with atypical hemolytic uremic syndrome, and analysis of the characteristics of aHUS patients in Japan

2011 - 2015 Analysis of the pathology and regulation system in pregnancy-associated thrombotic microangiopathy (TMA)

2011 - 2013 重症肝障害におけるADAMTS13の生体内存在様式と制御機構

2010 - 2012 Development of novel therapy for thrombotic microangiopathy after hematopoietic stem cell transplantation.

2009 - 2011 Heterotopic living-donor partial liver transplantation as a therapy for cure of hemophilia

2008 - 2010 Determination of ADAMTS13 and its regulation mechanism in severe liver disturbance

2008 - 2010 Elucidation of mechanism of thrombus formation in older people during sporting activity and preventive measure thereof

2007 - 2009 Analysis of TMA and VOD after allogenic stem cell transplantation

2007 - 2008 Analysis of functional relationships between VWF and ADAMTS13 under blood flow conditions

2006 - 2008 Clinical relevance of VWF cleaving protease as a new doagnostic marker in liver transplant recipients

2005 - 2007 ADAMTS13の解析と重症肝疾患における微小循環障害の発生機序の解明

2005 - 2007 Novel antithrombotic strategy based on the functional regulation of factor VIII/VWF complex

2005 - 2006 Potential Role of Dehydration on Thrombogenic Processes during Exercise

2004 - 2006 Analysis of ADATS13 in TMA patients with severe renal damage

2003 - 2005 Analysis of various type thrombosis with decreased ADAMTS13 activity

2003 - 2004 Study on the prediction of thrombosis formation during exercise

2001 - 2002 フォンビルブランド因子特異的切断酵素のモノクローナル抗体を用いた精製と構造機能解析

1999 - 2001 MOLECULAR DESIGN OF INHIBITORS ON THE FORMATION OF VON WILLEBRAND FACTOR-DEPENDENT PLATELET THROMBI

血栓性微小血管障害症(TMA)

フォンビルブランド因子特異的切断酵素(ADAMTS13)

placental ecto-ATP diphosphohydrolase(ATPDase)

von Willebrand factor cleaving protease.(ADAMTS13)

Show all

Papers (318)：

Okuda Makoto, Tanaka Asashi, Fujita Hiroshi, Endo Teruo, Matsuura Hideaki, Matsushita Tadashi, Sonoki Takashi, Takami Akiyoshi, Hasegawa Yuichi, Nozaki Akihito, et al. GUIDELINES FOR STORAGE AND MANAGEMENT OF BLOOD COMPONENTS FOR TRANSFUSION. Japanese Journal of Transfusion and Cell Therapy. 2024. 70. 6. 562-578
Masayuki Kubo, Kazuyasu Konko, Emi Kinoshita, Satoshi Uemae, Katsushi Kobayashi, Yoshinori Hayashi, Akihiko Kan, Yoshihiro Fujimura, Masanori Matsumoto. A novel automated chemiluminescent enzyme immunoassay (CLEIA) for ADAMTS13 activity enables accompanying measurements of the inhibitory autoantibodies. Journal of thrombosis and haemostasis : JTH. 2024
Masanori Matsumoto, Akihiko Shimono, Jun Yokosawa, Keiichiro Hirose, Edward Wang, Shoichi Maruyama. Correlation between a 2-week change in platelet count and clinical outcomes after the initiation of ravulizumab treatment in adult patients with atypical hemolytic uremic syndrome: post-hoc analysis of the phase III trial. Thrombosis journal. 2024. 22. 1. 93-93
Masahito Uchihara, Kazuya Sakai, Koki Shibata, Kenki Saito, Bernhard Lammle, Masanori Matsumoto. Immune-mediated thrombotic thrombocytopenic purpura with ischaemic cerebral infarction preceding onset of thrombocytopenia and microangiopathic haemolytic anaemia: A case report. British journal of haematology. 2024. 205. 4. 1649-1652
Kazunori Imada, Yoshitaka Miyakawa, Satoshi Ichikawa, Hitoji Uchiyama, Yasunori Ueda, Yasuhiro Hashimoto, Masashi Nishimi, Masako Tsukamoto, Sayaka Tahara, Masanori Matsumoto. Frontline use of rituximab may prevent ADAMTS13 inhibitor boosting during caplacizumab treatment in patients with iTTP: post hoc analysis of a phase 2/3 study in Japan. Thrombosis journal. 2024. 22. 1. 72-72

ｍore...

MISC (558)：

松本雅則. 【輸血のすべて】(Part 1)輸血療法のすべて輸血の過去,現在,未来特集のイントロダクションを兼ねて. Hospitalist. 2024. 12. 1. 1-7
酒井宏水, 東寛, 松本雅則. 備蓄・緊急投与が可能な人工赤血球製剤の開発状況備蓄・緊急投与が可能な人工赤血球製剤の実用化を目指す研究. 人工血液. 2024. 32. 1. 15-15
竹下泰史, 荻原建一, 酒井宏水, 松本雅則, 野上恵嗣. 備蓄・緊急投与が可能な人工赤血球製剤の開発状況人工赤血球が包括的止血機能に及ぼす影響のex vivo解析(第2報) トラネキサム酸同時添加の影響. 人工血液. 2024. 32. 1. 17-17
松本雅則. シン・補体介在性TMA(aHUS)の診断と治療. 日本輸血細胞治療学会誌. 2024. 70. 5. 巻末34-巻末34
松本雅則. 輸血ガイドラインの臨床現場での利用. 日本輸血細胞治療学会誌. 2024. 70. 5. 巻末51-巻末51

ｍore...

Patents (12)：

ｍore...

Books (6)：